Evotec stock hits new 52-week low as earnings losses weigh
Published on 08/19/2026 at 08:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec (ISIN DE0005664809) stock is trading close to a new 52-week low in August 2026 after recent sessions saw the shares touch $1.90 on the companys US listing, highlighting sustained pressure despite a rebound in broader equity markets as of August 19, 2026. Per recent market data, Evotec shares have also been quoted at 3.5480 on their European listing as of August 18, 2026, underscoring how the weakness spans both trading venues.
Shares test fresh 52-week lows
According to a recent market report Evotec stock on its US venue traded down to $1.8950 and last changed hands at $1.90 on August 18, 2026, with 8,258 shares in volume. This new low undercuts previous levels from earlier in 2026 and places the stock in a clearly defined downtrend, even as many biotechnology peers have stabilized.
A separate valuation overview shows a last US close at $1.900 with a 5-day change of -3.55 percent as of August 18, 2026. In the same snapshot, the year-to-date performance on that venue is reported at 0.00 percent, indicating that all of the recent pressure has come in the latest stretch rather than from a long slide since January 2026.
European listing and analyst targets
On the companys European listing, recent market data indicate a last close price of 3.320 on August 18, 2026, with the shares noted at 3.5480 and a year-to-date gain of 6.25 percent but a decline of 30.97 percent from a reference level. The same overview reports an average analyst target price of 4.586, compared with the current level of 3.320, implying upside of roughly 38 percent if the stock were to converge with consensus expectations.
Another quote page shows Evotec trading at 3.5480 on its German listing, down 0.3020 or 7.84 percent at the close of August 18, 2026. The data also indicate that the stock is down 26.02 percent over a recent comparison period, reinforcing the message from other portals that Evotec has underperformed significantly in 2026 compared with major European indices.
Recent revenue and earnings trends
In terms of operations, quarterly figures from a financial portal show that in the first quarter of fiscal 2026 Evotec reported revenue of 156.64 million and a loss of 121.94 million. That loss contrasts with the topline trend and reflects elevated research spending and other costs that have weighed on profitability.
The same dataset describes trailing twelve-month revenue of 745.04 million and a net loss attributable to common shareholders of 193.88 million as of the latest update in 2026. While these trailing figures aggregate multiple quarters and therefore mix different periods, they underline that Evotec is still loss-making on a cumulative basis even as it generates several hundred million in annual revenue. For investors, the gap between revenue and net income remains a central issue.
Analyst information in the portal highlights a distribution of recommendations and a target-price band from 3.50 to 10.00, with an average target around the mid-4 range and the current share price of 3.5480 sitting below that midpoint. Quantitatively, that implies that the stock is trading at a discount to the consensus fair value estimate, but the discount has been persistent against a backdrop of recurring quarterly losses.
Valuation and consensus context
The valuation sheet from one market-data site confirms that the recent US price of $1.900 as of August 18, 2026 has left Evotec in negative trailing earnings territory. Traditional price-to-earnings metrics are therefore not meaningful, and investors tend to focus on revenue multiples and the companys ability to translate its pipeline and service contracts into future profits.
On the European side, the consensus overview lists an average target price of 4.586 compared with the current 3.320. Numerically, this difference represents a potential gain of 1.266 per share, or almost 38 percent, if the stock were to move in line with the consensus. However, the same overview also signals that the share price has fallen almost 31 percent from a reference level, suggesting that the market has grown more skeptical than analysts about the near-term earnings path.
This divergence between price performance and target prices is often interpreted as a signal that either expectations will eventually be revised downward or that the stock could recover if execution improves. In Evotecs case, the sizable quarterly loss in the first quarter of fiscal 2026 adds weight to the cautious interpretation, because it shows that the companys current business mix is not yet generating sustainable profits.
Business model and partnering platform
Evotec positions itself as a drug discovery and development partner for pharmaceutical and biotechnology companies, combining fee-for-service contracts with co-owned pipeline assets. Under this model, the company aims to generate recurring revenue from research services while retaining upside from milestones and royalties on partnered compounds.
The revenue figure of 156.64 million for the first quarter of fiscal 2026 reflects this dual structure, as it includes contributions from multiple alliances across therapeutic areas. However, the reported quarterly loss of 121.94 million indicates that the company continues to invest heavily in its own platform, early-stage assets, and infrastructure, which increases operating expenses in the short term but is intended to support future growth.
Historically, trailing revenue of 745.04 million as reported in the twelve-month dataset underscores the scale that Evotec has already reached in global drug discovery markets. At the same time, the trailing net loss of 193.88 million shows that the company has yet to reach the efficiency level that would allow this revenue base to translate into positive net income. For long-term investors, the key question is how quickly Evotec can narrow this gap through higher-margin projects, cost discipline, or successful pipeline monetization.
Current share-price levels and investor implications
With Evotec stock on the US venue closing at $1.900 on August 18, 2026 and touching an intraday low of $1.8950, the shares are trading much closer to their 52-week lows than to the average analyst target price reported in August 2026. On the German listing, the price of 3.5480 at the August 18, 2026 close sits well below the 4.586 consensus target and has been accompanied by a decline of roughly 31 percent from a prior reference level.
This quantified gap between market price and analyst estimates suggests that investors are demanding a sizable risk premium before assigning higher valuations to Evotecs pipeline and service business. Given the first-quarter 2026 loss of 121.94 million against revenue of 156.64 million, the market appears to be prioritizing clear evidence of progress toward break-even or profitability over long-dated potential in early-stage programs.
In this context, catalysts such as upcoming quarterly reports, new partnering agreements, or updates on key clinical and preclinical assets could play an outsized role in determining whether the share price remains near its recent lows or begins to narrow the performance gap with consensus targets. Until then, the combination of sizable revenue, persistent losses, and a share price discount creates a complex risk-reward profile that investors will continue to monitor closely.
Representative collaboration platform
Evotecs business is anchored by its integrated discovery and development platform, which spans target identification, hit-to-lead optimization, preclinical development, and selected clinical contributions. Through this platform, the company partners with multiple large and mid-sized pharmaceutical firms to deliver discovery services and co-develop assets that may generate milestone and royalty streams if they advance successfully.
The revenue of 156.64 million in the first quarter of fiscal 2026 reflects ongoing project work under this platform for a diversified set of partners, while the trailing twelve-month revenue of 745.04 million points to a consistent level of demand across therapeutic areas. However, the corresponding loss of 121.94 million in that quarter and the trailing net loss of 193.88 million underline that this platform-centric model still requires high upfront investment in infrastructure and scientific capabilities.
Evotec stock and recent price context
As of the latest completed trading session on August 18, 2026, Evotecs German-listed shares closed at 3.5480, down 0.3020 or 7.84 percent on the day, while the US-listed shares ended at $1.900 after setting a new 52-week low in intraday trading at $1.8950. With the average target price on the European listing standing at 4.586 and the current level at 3.320 in one consensus snapshot, the stock trades at a notable discount to analyst expectations even as trailing revenue remains in the mid-hundreds of millions.
Read more
Further details on Evotec stock and fundamentals
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVT
Exchange: German listing and US quotation as referenced in recent market data
